Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer Ingelheim expands Metacam to guinea pigs
Guinea pigs tend to hide their pain, which often makes diagnosis difficult.
Product is first in the EU for the relief of post-surgical pain

Animal health business Boehringer Ingelheim has expanded its European Metacam indication to guinea pigs.

The decision follows an EU marketing Authorisation and means the product is now approved in guinea pigs for the alleviation of mild to moderate pain associated with soft tissue surgery.

Shawn Hooker from Boehringer Ingelheim explains: “As the market leader, it is our ambition to set new standards of care. We constantly invest in our brands – independent of their age – to prevent pain and suffering in animals.

“We believe that treating pain is a matter of animal welfare and that it should be standard of care in all species regardless of their size and number.”

Guinea pigs tend to hide their pain, which often makes diagnosis difficult. But according to the World Small Animal Veterinary Association, pain associated with surgery is 100 per cent predictable and treatable.

In a press release, Boehringer states: 'With Metacam®0.5mg/ml Oral Suspension for Cats and Guinea Pigs, Boehringer Ingelheim now offers the first NSAID in the EU for the relief of post-surgical pain in guinea pigs.'

For 25 years, Metacam has been used to relieve pain and reduce inflammation in a wide array of small and large animal species. The product is also used to alleviate pain and inflammation associated with acute or chronic musculoskeletal disorders such as osteoarthritis.

The new indication will be launched by Boehringer Ingelheim in all European countries throughout 2018.

Become a member or log in to add this story to your CPD history

FIVP publishes CMA Compliance Checklist

News Story 1
 FIVP has published a CMA Compliance Checklist to support independent practices with the Market Investigation Order.

The document includes deadlines for small and large businesses, with tick boxes for each of the tasks. The organisation also invites practices to contact them for support with requirements.

Rita Dingwall, FIVP chair, said: FIVP appreciates that navigating the new CMA requirements can feel daunting. We hope this checklist will make things a little easier, helping independent practices work through what is required with confidence. 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.